GlassScriptPhysician profile
Zahf Shaikh
NPI 1366976433
$3,697.54
in general payments reported to CMS, 2019-2025
19 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $258 · 2023: $1,125 · 2024: $789 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $723.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $392.75 | 2023-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $358.12 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.53 | 2023-2024 | Xifaxan, Trulance |
| Abbvie INC. | $295.84 | 2022-2025 | |
| Ardelyx, INC. | $277.80 | 2023-2025 | Ibsrela |
| Intra-Sana Laboratories | $222.99 | 2022-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Qol Medical, LLC | $214.23 | 2023-2025 | Sucraid, Sucraid |
| Mallinckrodt Hospital Products INC. | $154.09 | 2023-2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $145.86 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $119.72 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Biotech, INC. | $109.26 | 2024 | Tremfya, Stelara |
| Genzyme Corporation | $100.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.81 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $18.78 | 2025 | Vegzelma |
| Capsovision, INC. | $18.12 | 2023 | Capsocam Plus |
| Pfizer INC. | $16.89 | 2025 | |
| Intercept Pharmaceuticals, INC. | $15.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahf Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.